Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2015

Open Access 01-12-2015 | Case report

Optic glioma and precocious puberty in a girl with neurofibromatosis type 1 carrying an R681X mutation of NF1: case report and review of the literature

Authors: Mirjana Kocova, Elena Kochova, Elena Sukarova-Angelovska

Published in: BMC Endocrine Disorders | Issue 1/2015

Login to get access

Abstract

Background

Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder with an extremely variable phenotype. In childhood NF1 can be associated with optic glioma and central precocious puberty; the latter is more common when the optic chiasm is affected. The mutational spectrum of the NF1 gene is wide and complex; R681X is a rare severe mutation of the NF1 gene known to cause truncation of neurofibromin, with only ten reported cases in the literature so far.

Case presentation

We describe a girl with NF1 associated with early central precocious puberty appearing at 2.5 years of age and optic glioma affecting the optic chiasm as seen on magnetic resonance imaging (MRI). Genetic analysis confirmed the presence of R681X. Therapy with a gonadotropin-releasing hormone agonist was instituted with good response to therapy. The lesions on MRI were stable and no significant vision impairment was present during the 6 years of follow-up.

Conclusion

Of the ten reported cases of NF1 due to R681X, one has presented with optic glioma and none with precocious puberty. Thus, to our knowledge, this is the first reported case of this mutation presenting with precocious puberty. We believe that this is a contribution to the few reports on the phenotype of this mutation and to the future elucidation of genotype-phenotype correlations of this disease.
Literature
1.
go back to reference Williams VC, Lucas J, Babcock MA, GButmann DH, Koef B, Maria L. Neurofibromatosis Type 1 Revisited. Pediatrics. 2009;123:124–33.CrossRefPubMed Williams VC, Lucas J, Babcock MA, GButmann DH, Koef B, Maria L. Neurofibromatosis Type 1 Revisited. Pediatrics. 2009;123:124–33.CrossRefPubMed
2.
go back to reference Upadhyaya M. Neurofibromatisis type 1: diagnosis and recent advances. Expert Opin Med Diagn. 2010;4:307–22.CrossRefPubMed Upadhyaya M. Neurofibromatisis type 1: diagnosis and recent advances. Expert Opin Med Diagn. 2010;4:307–22.CrossRefPubMed
3.
go back to reference Szudek J, Evans DG, Friedman JM. Patterns of associations of clinical features in neurofibromatosis 1 (NF1). Hum Genet. 2003;112:289–97.PubMed Szudek J, Evans DG, Friedman JM. Patterns of associations of clinical features in neurofibromatosis 1 (NF1). Hum Genet. 2003;112:289–97.PubMed
4.
go back to reference Szudek J, Joe H, Friedman JM. Analysis of intrafamilial phenotypic variation in neurofibromatosis 1 (NF1). Genet Epidemiol. 2002;23:150–64.CrossRefPubMed Szudek J, Joe H, Friedman JM. Analysis of intrafamilial phenotypic variation in neurofibromatosis 1 (NF1). Genet Epidemiol. 2002;23:150–64.CrossRefPubMed
5.
go back to reference Neurofibromatosis. Conference statement. NIH Consensus Development Conference. Arch Neurol. 1988;45:575–8.CrossRef Neurofibromatosis. Conference statement. NIH Consensus Development Conference. Arch Neurol. 1988;45:575–8.CrossRef
6.
go back to reference Marchuk DA, Saulino AM, Tavakkol R, Swaroop M, Wallace MR, Andersen LB, et al. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics. 1991;11:931–40.CrossRefPubMed Marchuk DA, Saulino AM, Tavakkol R, Swaroop M, Wallace MR, Andersen LB, et al. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics. 1991;11:931–40.CrossRefPubMed
7.
go back to reference Fahsold R, Hoffmeyer S, Mischung C, Gille C, Ehlers C, Kucukceylan N, et al. Minor Lesion Mutational Spectrum of the Entire NF1 Gene Does Not Explain Its High Mutability but Points to a Functional Domain Upstream of the GAP-Related Domain. Am J Hum Genet. 2000;66:790–818.PubMedCentralCrossRefPubMed Fahsold R, Hoffmeyer S, Mischung C, Gille C, Ehlers C, Kucukceylan N, et al. Minor Lesion Mutational Spectrum of the Entire NF1 Gene Does Not Explain Its High Mutability but Points to a Functional Domain Upstream of the GAP-Related Domain. Am J Hum Genet. 2000;66:790–818.PubMedCentralCrossRefPubMed
8.
9.
go back to reference Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95 % of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat. 2000;15:541–55.CrossRefPubMed Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95 % of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat. 2000;15:541–55.CrossRefPubMed
10.
go back to reference Xu GF, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell. 1990;63:835–41.CrossRefPubMed Xu GF, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell. 1990;63:835–41.CrossRefPubMed
11.
go back to reference Bernards A, Snijders AJ, Hannigan GE, Murthy AE, Gusella JF. Mouse neurofibromatosis type 1 cDNA sequence reveals high degree of conservation of both coding and non-coding mRNA segments. Hum Mol Genet. 1993;2:645–50.CrossRefPubMed Bernards A, Snijders AJ, Hannigan GE, Murthy AE, Gusella JF. Mouse neurofibromatosis type 1 cDNA sequence reveals high degree of conservation of both coding and non-coding mRNA segments. Hum Mol Genet. 1993;2:645–50.CrossRefPubMed
12.
go back to reference The I, Hannigan GE, Cowley GS, Reginald S, Zhong Y, Gusella JF, et al. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science. 1997;276:791–4.CrossRefPubMed The I, Hannigan GE, Cowley GS, Reginald S, Zhong Y, Gusella JF, et al. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science. 1997;276:791–4.CrossRefPubMed
13.
go back to reference Ars E, Kruyer H, Morell M, Pros E, Serra E, Ravella A, et al. Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients. J Med Genet. 2003;40:e82.PubMedCentralCrossRefPubMed Ars E, Kruyer H, Morell M, Pros E, Serra E, Ravella A, et al. Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients. J Med Genet. 2003;40:e82.PubMedCentralCrossRefPubMed
14.
go back to reference Origone P, De Luca A, Bellini C, Buccino A, Mingarelli R, Costabel S, et al. Ten novel mutations in the human neurofibromatosis type 1 (NF1) gene in Italian patients. Hum Mutat. 2002;20:74–5.CrossRefPubMed Origone P, De Luca A, Bellini C, Buccino A, Mingarelli R, Costabel S, et al. Ten novel mutations in the human neurofibromatosis type 1 (NF1) gene in Italian patients. Hum Mutat. 2002;20:74–5.CrossRefPubMed
15.
go back to reference Castle B, Baser ME, Huson SM, Cooper DN, Upadhyaya M. Evaluation of genotype-phenotype correlations in neurofibromatosis type 1. J Med Genet. 2003;40:e109.PubMedCentralCrossRefPubMed Castle B, Baser ME, Huson SM, Cooper DN, Upadhyaya M. Evaluation of genotype-phenotype correlations in neurofibromatosis type 1. J Med Genet. 2003;40:e109.PubMedCentralCrossRefPubMed
16.
go back to reference Nishi T, Lee PS, Oka K, Levin VA, Tanase S, Morino Y, et al. Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation. Oncogene. 1991;6:1555–9.PubMed Nishi T, Lee PS, Oka K, Levin VA, Tanase S, Morino Y, et al. Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation. Oncogene. 1991;6:1555–9.PubMed
17.
go back to reference Zoller ME, Rembeck B, Oden A, Samuelsson M, Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer. 1997;79:2125–31.CrossRefPubMed Zoller ME, Rembeck B, Oden A, Samuelsson M, Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer. 1997;79:2125–31.CrossRefPubMed
18.
go back to reference Muir D, Neubauer D, Lim IT, Yachnis AT, Wallace MR. Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am J Pathol. 2001;158:501–13.PubMedCentralCrossRefPubMed Muir D, Neubauer D, Lim IT, Yachnis AT, Wallace MR. Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am J Pathol. 2001;158:501–13.PubMedCentralCrossRefPubMed
19.
go back to reference Habiby R, Silverman B, Listernick R, Charrow J. Precocious puberty in children with neurofibromatosis type 1. J Pediatrics. 1995;126(3):364–7.CrossRef Habiby R, Silverman B, Listernick R, Charrow J. Precocious puberty in children with neurofibromatosis type 1. J Pediatrics. 1995;126(3):364–7.CrossRef
20.
go back to reference Viridis R, Street ME, Bandello MA, Tripodi C, Donadio A, Villani AR, et al. Growth and pubertal disorders in neurofibromatosis type 1. J Pediatr Endocrinol Metab. 2003;16 Suppl 2:289–92. Viridis R, Street ME, Bandello MA, Tripodi C, Donadio A, Villani AR, et al. Growth and pubertal disorders in neurofibromatosis type 1. J Pediatr Endocrinol Metab. 2003;16 Suppl 2:289–92.
21.
go back to reference Gan HW, Phipps K, Aquilina K, Gaze MN, Hayward R, Spoudeas HA. Neuroendocrine morbidity after pediatric optic gliomas: a longitudinal analysis of 166 children over 30 years. J Clin Endocrinol Metab. 2015;100(10):3787–99.CrossRefPubMed Gan HW, Phipps K, Aquilina K, Gaze MN, Hayward R, Spoudeas HA. Neuroendocrine morbidity after pediatric optic gliomas: a longitudinal analysis of 166 children over 30 years. J Clin Endocrinol Metab. 2015;100(10):3787–99.CrossRefPubMed
22.
go back to reference Gerth C, Andrassi-Darida M, Bock M, Preising MN, Weber BH, Lorenz B. Phenotypes of 16 Stargardt macular dystrophy/fundus flavimaculatus patients with known ABCA4 mutations and evaluation of genotype-phenotype correlation. Graefes Arch Clin Exp Ophthalmol. 2002;240:628–38.CrossRefPubMed Gerth C, Andrassi-Darida M, Bock M, Preising MN, Weber BH, Lorenz B. Phenotypes of 16 Stargardt macular dystrophy/fundus flavimaculatus patients with known ABCA4 mutations and evaluation of genotype-phenotype correlation. Graefes Arch Clin Exp Ophthalmol. 2002;240:628–38.CrossRefPubMed
23.
go back to reference Ben-Salem S, Al-Shamsi AM, Ali BR, Al-Gazali L. The mutational spectrum of the NF1 gene in neurofibromatosis type I patients from UAE. Childs Nerv Syst. 2014;30:1183–9.CrossRefPubMed Ben-Salem S, Al-Shamsi AM, Ali BR, Al-Gazali L. The mutational spectrum of the NF1 gene in neurofibromatosis type I patients from UAE. Childs Nerv Syst. 2014;30:1183–9.CrossRefPubMed
24.
go back to reference Sharif S, Upadhyaya M, Ferner R, Majounie E, Shenton A, Baser M, et al. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype–phenotype correlations. J Med Genet. 2011;48:256–60.CrossRefPubMed Sharif S, Upadhyaya M, Ferner R, Majounie E, Shenton A, Baser M, et al. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype–phenotype correlations. J Med Genet. 2011;48:256–60.CrossRefPubMed
25.
go back to reference Segal L, Darvish-Zargar M, Dilenge ME, Ortenberg J, Polomeno RC. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. J AAPOS. 2010;14:155–8.CrossRefPubMed Segal L, Darvish-Zargar M, Dilenge ME, Ortenberg J, Polomeno RC. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. J AAPOS. 2010;14:155–8.CrossRefPubMed
26.
go back to reference Rutkowski JL, Wu K, Gutmann DH, Boyer PJ, Legius E. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet. 2000;9:1059–66.CrossRefPubMed Rutkowski JL, Wu K, Gutmann DH, Boyer PJ, Legius E. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet. 2000;9:1059–66.CrossRefPubMed
27.
go back to reference Avery RA, Ferner RE, Listernick R, Fisher MJ, Gutmann DH, Liu GT. Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. J Neurooncol. 2012;110:1–7.CrossRefPubMed Avery RA, Ferner RE, Listernick R, Fisher MJ, Gutmann DH, Liu GT. Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. J Neurooncol. 2012;110:1–7.CrossRefPubMed
29.
go back to reference Fisher MJ, Avery RA, Allen JC, Ardern-Holmes SL, Bilaniuk LT, Ferner RF, et al. Functional outcome measures for NF1 associated optic pathway glioma clinical trials. Neurology. 2013;18(21 Suppl1):S15–24.CrossRef Fisher MJ, Avery RA, Allen JC, Ardern-Holmes SL, Bilaniuk LT, Ferner RF, et al. Functional outcome measures for NF1 associated optic pathway glioma clinical trials. Neurology. 2013;18(21 Suppl1):S15–24.CrossRef
30.
go back to reference Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, et al. Visual outcomes in children with neurofibromatosis type 1 - associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012;14:790–7.PubMedCentralCrossRefPubMed Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, et al. Visual outcomes in children with neurofibromatosis type 1 - associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012;14:790–7.PubMedCentralCrossRefPubMed
31.
go back to reference Virdis R, Sigorini M, Laiolo A, Lorenzetti E, Street ME, Villani AR, et al. Neurofibromatosis type 1 and precocious puberty. J Pediatr Endocrinol Metab. 2000;13:841–4.PubMed Virdis R, Sigorini M, Laiolo A, Lorenzetti E, Street ME, Villani AR, et al. Neurofibromatosis type 1 and precocious puberty. J Pediatr Endocrinol Metab. 2000;13:841–4.PubMed
32.
go back to reference Maertens O, De Schepper S, Vandesimpele J, Brems H, Heyns I, Janssens S, et al. Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1. Am J Hum Genet. 2007;81:243.PubMedCentralCrossRefPubMed Maertens O, De Schepper S, Vandesimpele J, Brems H, Heyns I, Janssens S, et al. Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1. Am J Hum Genet. 2007;81:243.PubMedCentralCrossRefPubMed
Metadata
Title
Optic glioma and precocious puberty in a girl with neurofibromatosis type 1 carrying an R681X mutation of NF1: case report and review of the literature
Authors
Mirjana Kocova
Elena Kochova
Elena Sukarova-Angelovska
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2015
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-015-0076-4

Other articles of this Issue 1/2015

BMC Endocrine Disorders 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.